clostridium%20difficile%20infection
CLOSTRIDIUM DIFFICILE INFECTION
Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.

Laboratory Tests

Enzyme-Linked Immunoassay for Toxin

  • Most common test used to detect C difficile toxins
  • Lower sensitivity (63-99%) compared to the cytotoxin assay, but highly specific
  • Results are available w/in 2-6 hours
  • The test may need to be repeated in patients who initially had negative test results, but in whom C difficile infection is highly suspected

Nucleic Acid Amplification Tests (NAATs)

  • Superior to enzyme immunoassay for toxins as a diagnostic test for C difficile infection
  • Used only in acute infections; false positives are of concern

Stool Cytotoxin Assay

  • Gold standard for the diagnosis of C difficile-mediated infection
  • Highly sensitive & specific
  • Disadvantages: Expensive, results only available after 24-48 hours, requires a tissue culture facility

Stool Culture

  • Not helpful in diagnosis because the test is not specific for pathogenic toxin-producing strains of C difficile

Other Diagnostic Exams

Blood Chemistry

  • May show electrolyte imbalance & evidence of dehydration
    • Serum lactate may serve as indicator of disease severity before performing surgical treatment

Stool Exam

  • Grossly bloody stools are rare, but occult blood may be present in severe colitis

Sigmoidoscopy or Colonoscopy

  • Consider if there is a delay or difficulty in laboratory tests for C difficile

Imaging

Endoscopy

  • Indications for endoscopy
    • When there is a need for rapid diagnosis (eg fulminant disease)
    • In a patient who cannot produce stool because of ileus
    • As part of testing for other colonic diseases
    • May be considered in patients in whom laboratory exams for C difficile are negative but suspicion of the infection remains high
  • The pseudomembranous finding on bowel mucosa or on examination of a biopsy sample is pathognomonic of C difficile colitis
  • Findings may be normal in mild disease or may show only nonspecific colitis in moderate cases
  • Sigmoidoscopy alone may not detect abnormalities when lesions are confined to the right colon
  • Colonoscopy & sigmoidoscopy may be contraindicated in patients w/ fulminant colitis because of the risk of perforation

Computed Tomography (CT) Scan

  • Not useful in confirming the diagnosis of early or mild colitis
  • May be used as a confirmatory procedure for suspected C difficile infection when thickening of colonic mucosa is seen
  • Can quickly diagnose fulminant disease
    • Abdominal & pelvic CT scan may be done in patients w/ complicated infection
  • In cases involving the right colon, may reveal bowel wall edema & inflammation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Sep 2019
Mortality, length of stay (LOS) and hospital charges are significantly higher in chronic liver disease (CLD) patients with fractures, a recent study has shown. These findings are also associated with increased infection, bleeding and poorer wound healing.
01 Aug 2017
New drug applications approved by US FDA as of 16 - 30 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 04 Oct 2017

Using a reduced computed tomography (CT) dose to diagnose appendicitis in adolescents and young adults does not appear to affect clinical outcomes, and could potentially reduce the long-term risk of radiation-related cancers, according to results of the LOCAT* trial. 

22 Sep 2019
Oral supplementation with the gut commensal bacterium Akkermansia muciniphila safely improves several metabolic parameters in overweight or obese adults, as shown in a proof-of-concept study.